BTIG Research Issues Positive Forecast for CareDx (NASDAQ:CDNA) Stock Price

CareDx (NASDAQ:CDNA) had its target price boosted by BTIG Research from $22.00 to $25.00 in a research report report published on Thursday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of CareDx in a report on Wednesday, October 8th. William Blair assumed coverage on shares of CareDx in a research report on Tuesday, August 26th. They set a “market perform” rating for the company. Wells Fargo & Company lowered their price target on shares of CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a report on Friday, August 8th. Craig Hallum dropped their price objective on CareDx from $40.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, July 18th. Finally, Zacks Research lowered CareDx from a “hold” rating to a “strong sell” rating in a report on Monday, October 20th. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $26.00.

CareDx Trading Up 4.1%

Shares of CDNA stock traded up $0.61 during trading on Thursday, hitting $15.62. The company’s stock had a trading volume of 1,435,003 shares, compared to its average volume of 1,213,877. The company has a market cap of $831.41 million, a PE ratio of 15.31 and a beta of 2.50. The business has a fifty day moving average of $14.49 and a 200-day moving average of $15.60. CareDx has a 52 week low of $10.96 and a 52 week high of $26.37.

CareDx (NASDAQ:CDNA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.10). CareDx had a return on equity of 18.03% and a net margin of 17.97%.The business had revenue of $100.06 million during the quarter, compared to analysts’ expectations of $95.25 million. During the same period in the prior year, the firm posted ($0.14) EPS. The firm’s revenue for the quarter was up 20.7% on a year-over-year basis. CareDx has set its FY 2025 guidance at EPS. As a group, research analysts predict that CareDx will post -0.9 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Principal Financial Group Inc. increased its position in shares of CareDx by 3.4% during the first quarter. Principal Financial Group Inc. now owns 19,624 shares of the company’s stock valued at $348,000 after buying an additional 640 shares during the period. Sei Investments Co. boosted its position in shares of CareDx by 1.7% in the first quarter. Sei Investments Co. now owns 47,921 shares of the company’s stock valued at $851,000 after acquiring an additional 816 shares during the period. Fuller & Thaler Asset Management Inc. boosted its position in shares of CareDx by 3.9% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock valued at $425,000 after acquiring an additional 900 shares during the last quarter. MCF Advisors LLC grew its holdings in shares of CareDx by 292.9% during the second quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after purchasing an additional 996 shares in the last quarter. Finally, Cetera Trust Company N.A increased its position in shares of CareDx by 11.2% in the second quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock worth $238,000 after purchasing an additional 1,225 shares during the last quarter.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.